Evidence map›Paper›PMID 39769315›Full record

ArticleInternational journal of molecular sciences2024

Au@

Nasrin Abbasi Gharibkandi, Agnieszka Majkowska-Pilip, Rafał Walczak, Mateusz Wierzbicki, Aleksander Bilewicz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nasrin Abbasi GharibkandiCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland.
Agnieszka Majkowska-PilipCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland.ORCID 0000-0001-9449-6411
Rafał WalczakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland.ORCID 0000-0002-0308-7223
Mateusz WierzbickiInstitute of Biology, Warsaw University of Life Sciences, Ciszewskiego 8 St., 02-786 Warsaw, Poland.ORCID 0000-0003-3623-8929
Aleksander BilewiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland.ORCID 0000-0003-2490-3303

Funding

National Science Center Poland grant no 2022/45/B/ST5/01861 (OPUS), and grant no 2019/35/B/ST4/01433 (OPUS)
6 · The paper itself

Abstract

Apart from HER2-positive, triple-negative breast cancer (TNBC) is the second most highly invasive type of breast cancer. Although TNBC does not overexpress HER2 receptors, it has been observed that EGFR protein expression is present in this specific type of tumor, making it an attractive target for immune and radiopharmaceutical treatments. In our current study, we used

Indexed as

GoldMetal NanoparticlesPanitumumabTriple Negative Breast NeoplasmsCell Line, TumorElectronsErbB ReceptorsFemaleHumansPalladiumErbB ReceptorsGoldPalladiumPanitumumab109Pd/109mAg in vivo generatorradioimmunotherapytriple-negative breast cancer

Identifiers

PMID39769315
PMCPMC11676729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.